Prof. Dr. RANA KARABUDAK

Yayın Ağı

Makaleler 125

1. Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience

ÇAKAN ERCAN M., Demirel E., ÇİMEN B., ACAR ÖZEN N. P., Colpak I., Karabudak R., et al.

JOURNAL OF NEUROIMMUNOLOGY , 2025 (SCI-Expanded, Scopus)

2. Evaluating Motor Imagery Capabilities in Fatigued Versus Non-Fatigued Individuals With Multiple Sclerosis Without Cognitive Impairment

Sekercan G., FİL BALKAN A., YETKİN M. F., Karabudak R., Tuncer A., SALCI Y.

NEUROREHABILITATION AND NEURAL REPAIR , 2025 (SCI-Expanded, Scopus)

3. Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families

Buyukgol F., GÜRDAMAR B., ALUÇLU M. U., BECKMANN Y., Bilguvar K., BOZ C., et al.

SCIENTIFIC REPORTS , sa.1, 2025 (SCI-Expanded, Scopus)

4. Can serum C3/C4 complement ratio be used in the differential diagnosis of central nervous system demyelinating diseases?

ÇAKAN ERCAN M., ÇİMEN B., ACAR ÖZEN N. P., SARA M. Y., KARABUDAK R., Tuncer A.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , 2025 (SCI-Expanded, Scopus)

5. Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

Hartung H., Benedict R. H. B., Berger T., Bermel R. A., Brochet B., Carroll W. M., et al.

NEUROLOGY , cilt.103, sa.12, 2024 (SCI-Expanded, Scopus)

6. Long-term Safety and Efficacy of Rituximab in Autoimmune Central Nervous System Disorders: Insights from a Single-Center Cohort

Ozbek E. D., Acar N. P., ÇOLPAK IŞIKAY A. İ., Tan E., KARABUDAK R., TUNCER M. A.

MULTIPLE SCLEROSIS JOURNAL , sa.3, ss.1102-1103, 2024 (SCI-Expanded, Scopus)

7. Vaccination Strategies In Individuals With Multiple Sclerosis: Delphi Consensus

ÇİNAR B. P., Tuncer A., ÇETİNKAYA L., Aluclu U., BECKMANN Y., BOZ C., et al.

MULTIPLE SCLEROSIS JOURNAL , sa.3, ss.829-830, 2024 (SCI-Expanded, Scopus)

8. Evaluation of Myeloid-Derived Suppressor Cells in Newly Diagnosed MS Patients

Acar N. P., Yanik H., ESENDAĞLI G., KARABUDAK R., TUNCER M. A.

MULTIPLE SCLEROSIS JOURNAL , sa.3, ss.887-888, 2024 (SCI-Expanded, Scopus)

9. A standardised definition of progression independent of relapse activity in multiple sclerosis

Mueller J., Sharmin S., Lorscheider J., Ozakbas S., KARABUDAK R., Horakova D., et al.

MULTIPLE SCLEROSIS JOURNAL , sa.3, ss.442-445, 2024 (SCI-Expanded, Scopus)

10. Choroid Plexus Enlargement and Associated Thalamus Atrophy Initiate in Radiologically Isolated Syndrome

Ozbek E. D., Acar N. P., Gormus M., KAYA K., AKÇİÇEK E., Bachhuber F., et al.

MULTIPLE SCLEROSIS JOURNAL , sa.3, ss.1251, 2024 (SCI-Expanded, Scopus)

11. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial

Hartung H., Berger T., Bermel R. A., Brochet B., Carroll W. M., Holmoy T., et al.

JOURNAL OF NEUROLOGY , cilt.271, sa.7, ss.4348-4360, 2024 (SCI-Expanded, Scopus)

12. Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis

Aprea M. G., Schiavetti I., Portaccio E., Ballerini C., Bonavita S., Buscarinu M., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.30, sa.6, ss.707-713, 2024 (SCI-Expanded, Scopus)

13. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study

Spelman T., Simoneau G., Hyde R., Kuhelj R., Alroughani R., Ozakbas S., et al.

Neurology , cilt.102, sa.7, 2024 (SCI-Expanded, Scopus)

14. Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care

Ozen N. P. A., Dursun E. G., Tuncer A., KARABUDAK R.

Multiple Sclerosis and Related Disorders , cilt.84, 2024 (SCI-Expanded, Scopus)

15. Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study

Öztürk B., Taşkıran E., Demir S., TUNCER M. A., KÜRTÜNCÜ M., KARABUDAK R., et al.

Multiple Sclerosis Journal , 2024 (SCI-Expanded, Scopus)

16. The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study

Levitz D., Foong Y. C., Sanfilippo P., Spelman T., Rath L., Roldan A., et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS , cilt.17, 2024 (SCI-Expanded, Scopus)

17. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

Li Y., Saul A., Taylor B., Ponsonby A., Simpson-Yap S., Blizzard L., et al.

Journal of neurology , cilt.271, sa.1, ss.472-485, 2024 (SCI-Expanded, Scopus)

18. Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry

Signori A., Ponzano M., Kalincik T., Ozakbas S., Horakova D., Havrdova E. K., et al.

Journal of Neurology, Neurosurgery and Psychiatry , 2024 (SCI-Expanded, Scopus)

19. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al.

Journal of neurology, neurosurgery, and psychiatry , cilt.94, sa.12, ss.1004-1011, 2023 (SCI-Expanded, Scopus)

20. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sánchez M. M., Ozakbas S., et al.

Brain : a journal of neurology , cilt.146, sa.11, ss.4633-4644, 2023 (SCI-Expanded, Scopus)

21. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment

Sen S., Tuncer A., Terzi M., BÜNÜL S. D., Ozen-Acar P., Altunrende B., et al.

Multiple Sclerosis and Related Disorders , cilt.79, 2023 (SCI-Expanded, Scopus)

22. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial

Lebrun-Frénay C., SİVA A., Sormani M. P., Landes-Chateau C., Mondot L., Bovis F., et al.

JAMA neurology , cilt.80, sa.10, ss.1080-1088, 2023 (SCI-Expanded, Scopus)

23. Reliability and validity of the glittre activities of daily living test in fully ambulatory multiple sclerosis patients

Kaya G., KÖSE N., SALCI Y., ARMUTLU K., Karakaya J., Tuncer A., et al.

Irish Journal of Medical Science , cilt.192, sa.5, ss.2379-2386, 2023 (SCI-Expanded, Scopus)

24. Disability accrual in primary and secondary progressive multiple sclerosis

Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al.

Journal of Neurology, Neurosurgery and Psychiatry , cilt.94, sa.9, ss.707-717, 2023 (SCI-Expanded, Scopus)

25. Sars-CoV2 infection in pregnant women with multiple sclerosis

Aprea M. G., Schiavetti I., Portaccio E., Ballerini C., Battaglia M. A., Bergamaschi R., et al.

Multiple Sclerosis Journal , cilt.29, sa.9, ss.1090-1098, 2023 (SCI-Expanded, Scopus)

26. Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

Cohen M., Thomel-Rocchi O., SİVA A., Okuda D. T., KARABUDAK R., EFENDİ H., et al.

Multiple Sclerosis Journal , cilt.29, sa.9, ss.1099-1106, 2023 (SCI-Expanded, Scopus)

27. Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center

BAHAR Y., YILDIZ E., Bahar A. R., KARABUDAK R.

Turkish Journal of Medical Sciences , cilt.53, sa.4, ss.962-969, 2023 (SCI-Expanded, Scopus, TRDizin)

28. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

Kalincik T., Sharmin S., Roos I., Freedman M. S., Atkins H., Burman J., et al.

JAMA Neurology , cilt.80, sa.7, ss.702-713, 2023 (SCI-Expanded, Scopus)

29. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?

Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., et al.

Multiple Sclerosis and Related Disorders , cilt.75, 2023 (SCI-Expanded, Scopus)

30. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Daruwalla C., Shaygannejad V., ÖZAKBAŞ S., Havrdova E. K., Horakova D., Alroughani R., et al.

Multiple sclerosis (Houndmills, Basingstoke, England) , cilt.29, sa.7, ss.875-883, 2023 (SCI-Expanded, Scopus)

31. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis

BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al.

Neurological Sciences , cilt.44, sa.6, ss.2121-2129, 2023 (SCI-Expanded, Scopus)

32. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.

European Journal of Neurology , cilt.30, sa.4, ss.1014-1024, 2023 (SCI-Expanded, Scopus)

33. External validation of a clinical prediction model in multiple sclerosis

Moradi N., Sharmin S., Malpas C. B., Shaygannejad V., Terzi M., BOZ C., et al.

Multiple Sclerosis Journal , cilt.29, sa.2, ss.261-269, 2023 (SCI-Expanded, Scopus)

34. Comparative effectiveness in multiple sclerosis: A methodological comparison

Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., et al.

Multiple Sclerosis Journal , cilt.29, 2023 (SCI-Expanded, Scopus)

35. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

Spelman T., Magyari M., Butzkueven H., van der Walt A., Vukusic S., Trojano M., et al.

FRONTIERS IN NEUROLOGY , cilt.14, 2023 (SCI-Expanded, Scopus)

36. The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis

Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., et al.

Noropsikiyatri Arsivi , cilt.60, sa.3, ss.252-256, 2023 (SCI-Expanded, Scopus, TRDizin)

37. Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

Tuncer A., Kürtüncü M., Terzi M., UYGUNOĞLU U., Göncüoğlu C., Yüceyar A. N., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.1, ss.323-332, 2023 (SCI-Expanded, Scopus, TRDizin)

38. The acute effect of cervical mobilization on balance in patients with multiple sclerosis: a single-blind, randomized, controlled trial

KARANFİL E., SALCI Y., FİL BALKAN A., Tuncer A., KARABUDAK R.

Neurological Research , cilt.46, sa.1, ss.65-71, 2023 (SCI-Expanded, Scopus)

39. Perivascular PDGFRB+ cells accompany lesion formation and clinical evolution differentially in two different EAE models

Şekerdağ-Kılıç E., Ulusoy C., Atak D., Özkan E., Gökyüzü A. B., Seyaj S., et al.

Multiple Sclerosis and Related Disorders , cilt.69, 2023 (SCI-Expanded, Scopus)

40. Defining the experiences of adolescent patients with multiple sclerosis in transition from pediatric care to adult care

Yilmaz D. Y., YARDIMCI F., Erdemir F., KARABUDAK R.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.68, 2022 (SCI-Expanded, Scopus)

41. Combined Central and Peripheral Demyelination in a Case With Sjogren Syndrome

SÖKMEN O., GÖÇMEN R., NURLU G., KARABUDAK R.

NEUROLOGIST , cilt.27, sa.6, ss.354-356, 2022 (SCI-Expanded, Scopus)

42. Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION , cilt.9, sa.6, 2022 (SCI-Expanded, Scopus)

43. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.93, ss.1330-1337, 2022 (SCI-Expanded, Scopus)

44. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta

Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.66, 2022 (SCI-Expanded, Scopus)

45. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis

Ponzano M., Schiavetti I., Bovis F., Landi D., Carmisciano L., De Rossi N., et al.

Multiple Sclerosis and Related Disorders , cilt.63, 2022 (SCI-Expanded, Scopus)

46. Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-a-vis the differential prognosis and differentiation of Multiple Sclerosis' subgroups

Karaca Y., BALEANU D., KARABUDAK R.

KNOWLEDGE-BASED SYSTEMS , cilt.246, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study

Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.

NEUROLOGY , cilt.98, sa.24, 2022 (SCI-Expanded, Scopus)

48. Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Zhong M., van der Walt A., Stankovich J., Kalincik T., Buzzard K., Skibina O., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.28, sa.6, ss.958-969, 2022 (SCI-Expanded, Scopus)

49. Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity?

ARSLAN D., Acar-Ozen P., GÖÇMEN R., ELİBOL B., KARABUDAK R., Tuncer A.

NEUROLOGICAL SCIENCES , cilt.43, sa.3, ss.1569-1573, 2022 (SCI-Expanded, Scopus)

50. The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?

Sen S., Tuncer A., ÖZAKBAŞ S., Uzunkopru C., Baba C., Demir S., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.58, 2022 (SCI-Expanded, Scopus)

51. Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder

Topkan T. A., SÖKMEN O., Kocer B., KARABUDAK R., UYAR GÖÇÜN F. P.

NEUROLOGIA I NEUROCHIRURGIA POLSKA , cilt.56, sa.3, ss.285-287, 2022 (SCI-Expanded, Scopus)

52. Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression

Sevim S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., Tasdelen B., İDİMAN E., et al.

ARQUIVOS DE NEURO-PSIQUIATRIA , cilt.80, ss.168-172, 2022 (SCI-Expanded, Scopus)

53. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Arslan B., Arslan G. A., Tuncer A., KARABUDAK R., SEPİCİ DİNÇEL A.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES , cilt.22, sa.5, ss.699-706, 2022 (SCI-Expanded, Scopus)

54. Factors associated with fingolimod rebound: A single center real-life experience

Goncuoglu C., Tuncer A., Bayraktar-Ekincioglu A., Cagan C. A., Acar-Ozen P., ÇAKAN M., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.56, 2021 (SCI-Expanded, Scopus)

55. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018

Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., TERZİ M., et al.

CNS DRUGS , cilt.35, sa.10, ss.1097-1106, 2021 (SCI-Expanded, Scopus)

56. Evaluation of Thiol Homeostasis in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

Arslan B., Arslan G. A., Tuncer A., KARABUDAK R., SEPİCİ DİNÇEL A.

FRONTIERS IN NEUROLOGY , cilt.12, 2021 (SCI-Expanded, Scopus)

57. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sorensen P. S., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.53, 2021 (SCI-Expanded, Scopus)

58. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy

Acar N. P., Tuncer A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., et al.

JOURNAL OF NEUROIMMUNOLOGY , cilt.347, 2020 (SCI-Expanded, Scopus)

59. Factors Affecting Bone Mineral Density in Male Patients with Primary Progressive Multiple Sclerosis

Arican A. C., Kutsal Y. G., Acar N. P., AKBIYIK F., KARAHAN S., KARABUDAK R.

TURK OSTEOPOROZ DERGISI-TURKISH JOURNAL OF OSTEOPOROSIS , cilt.26, sa.2, ss.115-120, 2020 (ESCI, Scopus, TRDizin)

60. 'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'

Sevim S., Demirkiran M., TERZİ M., YÜCEYAR A. N., Tasdelen B., İDİMAN E., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.42, 2020 (SCI-Expanded, Scopus)

61. The COVID-19 from Neurological Overview

Acar T., Demirel E. A., AFSAR N., AKÇALI A., Demir G. A., ALAGÖZ A. N., et al.

TURKISH JOURNAL OF NEUROLOGY , cilt.26, sa.2, ss.58-108, 2020 (ESCI, Scopus, TRDizin)

62. Early clinical markers of aggressive multiple sclerosis

Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.

BRAIN , cilt.143, ss.1400-1413, 2020 (SCI-Expanded, Scopus)

63. Investigation of Adaptation to Successive Postural Perturbations in Patients with Multiple Sclerosis

SALCI Y., KARANFİL E., AYVAT E., Balkan A. F., KARAKAYA KARABULUT J., AKSOY S., et al.

TURKISH JOURNAL OF NEUROLOGY , cilt.26, sa.1, ss.24-29, 2020 (ESCI, Scopus, TRDizin)

64. Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohort

Vural A., Derle E., Sayat-Gurel G., KARABUDAK R., Tuncer A.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.38, 2020 (SCI-Expanded, Scopus)

65. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder

Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.38, 2020 (SCI-Expanded, Scopus)

66. Retinal degeneration is associated with brain volume reduction and prognosis in radiologically isolated syndrome

Vural A., Okar S., Kurne A., Sayat-Gurel G., Acar N. P., KARABULUT E., et al.

MULTIPLE SCLEROSIS JOURNAL , cilt.26, sa.1, ss.38-47, 2020 (SCI-Expanded, Scopus)

67. Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey

Kurtuncu M., Tuncer A., Uygunoglu U., Caliskan Z., Kokenli Paksoy A., EFENDİ H., et al.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.56, sa.4, ss.269-272, 2019 (SCI-Expanded, Scopus, TRDizin)

68. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis

BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.36, 2019 (SCI-Expanded, Scopus)

69. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY , cilt.90, sa.4, ss.458-468, 2019 (SCI-Expanded, Scopus)

70. Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course

Kaymakamzade B., Kilic A. K., Tuncer Kurne A., KARABUDAK R.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.56, sa.1, ss.23-26, 2019 (SCI-Expanded, Scopus, TRDizin)

71. Analysis of Peripapillary Retinal Nerve Fiber Layer and Macular Volume in Patients with Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Healthy Controls Using Spectral Domain Optical Coherence Tomography in a Turkish Cohort

ÇOLPAK IŞIKAY A. İ., GÜLMEZ SEVİM D., Tuncer A., Diker S., KARABUDAK R., Kadayificilar S., et al.

TURKISH JOURNAL OF NEUROLOGY , cilt.25, sa.1, ss.26-31, 2019 (ESCI, Scopus, TRDizin)

72. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?

Kocyigit D., YALÇIN M. U., Gurses K. M., Tokgozoglu L., KARABUDAK R.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.27, ss.276-280, 2019 (SCI-Expanded, Scopus)

73. Cerebrospinal fluid oligoclonal banding patterns and intrathecal immunoglobulin synthesis: Data comparison from a wide patient group

PINAR A., Kurne A. T., LAY İ., Acar N. P., KARAHAN S., KARABUDAK R., et al.

NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY , cilt.35, sa.1, ss.21-28, 2018 (SCI-Expanded, Scopus, TRDizin)

74. Validity and reliability of the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) in multiple sclerosis patients with ataxia

SALCI Y., FİL BALKAN A., KEKLİCEK H., ÇETİN B., ARMUTLU K., Dolgun A., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.18, ss.135-140, 2017 (SCI-Expanded, Scopus)

75. Multiple Skleroz Hastalarının Tamamlayıcı ve Alternatif Tedavi Kullanım Durumlarının Belirlenmesi.

DURU AŞİRET G., Düğer ü., KAPUCU S., TUNCER M. A., KARABUDAK R.

Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi , cilt.6, sa.3, ss.1-6, 2017 (TRDizin)

76. Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study

SALCI Y., FİL BALKAN A., ARMUTLU K., Yildiz F. G., Kurne A., AKSOY S., et al.

DISABILITY AND REHABILITATION , cilt.39, sa.26, ss.2626-2632, 2017 (SCI-Expanded, SSCI, Scopus)

77. Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?

Dahdaleh M., Alroughani R., Aljumah M., AlTahan A., Alsharoqi I., Bohlega S. A., et al.

INTERNATIONAL JOURNAL OF NEUROSCIENCE , cilt.127, sa.10, ss.944-951, 2017 (SCI-Expanded, Scopus)

78. The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome

Diker S., Has A. C., Kurne A., GÖÇMEN R., Oguz K. K., KARABUDAK R.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.10, ss.14-21, 2016 (SCI-Expanded, Scopus)

79. Unfavorable outcome of pediatric onset multiple sclerosis: Follow-up in the pediatric and adult neurology departments of one referral center, in Turkey

Derle E., Kurne A. T., KONUŞKAN B., KARABUDAK R., Anlar B.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.9, ss.1-4, 2016 (SCI-Expanded, Scopus)

80. Acute Disseminated Encephalomyelitis after Oral Therapy with Herbal Extracts: A Case Report

Kaymakamzade B., KARABUDAK R., Kurne A. T., NURLU G.

BALKAN MEDICAL JOURNAL , cilt.33, sa.3, ss.366-369, 2016 (SCI-Expanded, Scopus, TRDizin)

81. Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin

Vural A., GÖÇMEN R., KURNE A. T., OGUZ K. K., TEMUÇİN Ç. M., TAN E., et al.

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES , cilt.43, sa.1, ss.149-156, 2016 (SCI-Expanded, Scopus)

82. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks

Alroughani R., Altintas A., Al Jumah M., Sahraian M., Alsharoqi I., AlTahan A., et al.

MULTIPLE SCLEROSIS INTERNATIONAL , cilt.2016, 2016 (ESCI)

83. Assessment of the effect of cigarette smoking on regional brain volumes and lesion load in patients with clinically isolated syndrome

Durhan G., Diker S., Has A. C., Karakaya J., Kurne A. T., KARABUDAK R., et al.

INTERNATIONAL JOURNAL OF NEUROSCIENCE , cilt.126, sa.9, ss.805-811, 2016 (SCI-Expanded, Scopus)

84. Case Study Application for C-Support Vector Classification: The Estimation of MS Subgroup Classification with Selected Kernels and Parameters

Karaca Y., Hayta S., KARABUDAK R.

EUROPEAN JOURNAL OF PURE AND APPLIED MATHEMATICS , cilt.9, sa.2, ss.196-215, 2016 (ESCI, Scopus)

85. Rituximab in Turkish neuromyelitis optica patients with limited response to other immunosuppressants

ERDENER Ş. E., KURNE A. T., DIKER S., KARABUDAK R.

JOURNAL OF THE NEUROLOGICAL SCIENCES , cilt.359, ss.106-107, 2015 (SCI-Expanded, Scopus)

86. Magnetic Resonance Imaging as a Major Milestone in Multiple Sclerosis Diagnosis and Treatment

KARABUDAK R.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY , cilt.52, 2015 (SCI-Expanded, Scopus, TRDizin)

87. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features

Altintas A., KARABUDAK R., Balci B. P., TERZİ M., Soysal A., Saip S., et al.

NEUROLOGIST , cilt.20, sa.4, ss.61-66, 2015 (SCI-Expanded, Scopus)

88. Functional clinical outcomes in multiple sclerosis: Current status and future prospects

KARABUDAK R., Dahdaleh M., Aljumah M., Alroughani R., Alsharoqi I. A., AlTahan A. M., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.4, sa.3, ss.192-201, 2015 (SCI-Expanded, Scopus)

89. Linear Modeling of Multiple Sclerosis and Its Subgroubs

Karaca Y., OSMAN O., KARABUDAK R.

TURKISH JOURNAL OF NEUROLOGY , cilt.21, sa.1, ss.7-12, 2015 (ESCI, Scopus)

90. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey

KARABUDAK R., Karampampa K., Caliskan Z.

JOURNAL OF MEDICAL ECONOMICS , cilt.18, sa.1, ss.69-75, 2015 (SCI-Expanded, Scopus)

91. Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes' stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide

KILIÇ A., ESENDAĞLI G., SAYAT G., TALİM B., KARABUDAK R., KURNE A.

AUTOIMMUNITY , cilt.48, sa.6, ss.423-428, 2015 (SCI-Expanded, Scopus)

92. The Course of Myasthenia Gravis with Systemic Lupus Erythematosus

Bekircan-Kurt C. E., Kurne A. T., Erdem-Ozdamar S., Kalyoncu U., Karabudak R., Tan E.

EUROPEAN NEUROLOGY , cilt.72, ss.326-329, 2014 (SCI-Expanded, Scopus)

93. Mass Lesions in the Brain: Tumor or Multiple Sclerosis? Clinical and Imaging Characteristics and Course from a Single Reference Center

Kilic A. K., Tuncer Kurne A., Karli Oguz K., Soylemezoglu F., KARABUDAK R.

TURKISH NEUROSURGERY , cilt.23, sa.6, ss.728-735, 2013 (SCI-Expanded, Scopus, TRDizin)

94. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy

ESENDAĞLI G., Kurne A. T., Sayat G., Kilic A. K., Guc D., KARABUDAK R.

JOURNAL OF NEUROIMMUNOLOGY , cilt.255, ss.81-84, 2013 (SCI-Expanded, Scopus)

95. Comparing routine neurorehabilitation program with trunk exercises based on Bobath concept in multiple sclerosis: Pilot study

Keser I., Kirdi N., Meric A., Kurne A. T., Karabudak R.

JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT , cilt.50, sa.1, ss.133-140, 2013 (SCI-Expanded, SSCI, Scopus)

96. Myasthenia Gravis; Single Entity, Variable Clinical Features: Ten Years of Clinical Experience in a Tertiary Care Center Ten Years Clinical Experience of a Tertiary Care Center

BEKIRCAN-KURT C. E., KURNE A., ERDEM ÖZDAMAR S., KARABUDAK R., KANSU T., TAN E.

JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH , cilt.30, sa.1, ss.135-143, 2013 (SCI-Expanded, Scopus, TRDizin)

97. Lack of association of the CD14/C-159T polymorphism with susceptibility and progression parameters in Turkish multiple sclerosis patients

Kurne A., Sayat G., Aydin O. F., Turgutoglu N., Terzi M., Sackesen C., et al.

JOURNAL OF NEUROIMMUNOLOGY , cilt.250, ss.83-86, 2012 (SCI-Expanded, Scopus)

98. Involvement of Autonomic Nervous System and its Relationship With Cranial and Cervical Spinal MRI Findings In Patients With Multiple Sclerosis

Ciftci O., KESER İ., Kurne A., Bosnak Guclu M., Karli Oguz K., Soylu R., et al.

JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH , cilt.29, sa.2, ss.181-191, 2012 (SCI-Expanded, Scopus, TRDizin)

99. Improvement of muscle strength and fatigue with high voltage pulsed galvanic stimulation in multiple sclerosis patients - a non-randomized controlled trial

Korkmaz N. C., Kirdi N., TEMUÇİN Ç. M., ARMUTLU K., Yakut Y., KARABUDAK R.

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION , cilt.61, sa.8, ss.736-743, 2011 (SCI-Expanded, Scopus)

100. Comparing routine neurorehabilitation programme with callisthenic exercises in multiple sclerosis

KESER İ., MERİÇ A., KIRDI N., Kurne A., KARABUDAK R.

NEUROREHABILITATION , cilt.29, sa.1, ss.91-98, 2011 (SCI-Expanded, SSCI, Scopus)

101. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy

Kurne A., Guc D., CANPINAR H., Aydin O. F., Sayat G., Yorubulut M., et al.

ACTA NEUROLOGICA SCANDINAVICA , cilt.123, sa.1, ss.8-12, 2011 (SCI-Expanded, Scopus)

102. A comparative assessment of cerebral white matter by magnetization transfer imaging in early- and adult-onset multiple sclerosis patients matched for disease duration

Oguz K. K., Kurne A., Aksu A. O., Taskiran A., KARABULUT E., KARABUDAK R.

JOURNAL OF NEUROLOGY , cilt.257, sa.8, ss.1309-1315, 2010 (SCI-Expanded, Scopus)

103. Familial Mediterranean fever and central nervous system involvement: a case series.

KALYONCU U., Eker A., Oguz K. K., Kurne A., Kalan I., Topcuoglu A. M., et al.

Medicine , cilt.89, sa.2, ss.75-84, 2010 (SCI-Expanded, Scopus)

104. Recurrent optic neuritis: clues from a long-term follow up study of recurrent and bilateral optic neuritis patients

Kurne A., KARABUDAK R., YALÇIN ÇAKMAKLI G., Gursoy-Ozdemir Y., Aydin P., Ilksen-Colpak A., et al.

EYE AND BRAIN , cilt.2, ss.15-20, 2010 (ESCI, Scopus)

105. Cumulative Corticosteroid Doses and Osteoporosis in Patients with Multiple Sclerosis

Arslan S., Celiker R., KARABUDAK R.

TURKISH JOURNAL OF RHEUMATOLOGY , cilt.25, sa.4, ss.191-195, 2010 (SCI-Expanded, Scopus, TRDizin)

106. The Effect of Walking Distance on EDSS Score in Patients with Multiple Sclerosis

Tombak K. B., ARMUTLU K., KARABUDAK R.

TURKISH JOURNAL OF NEUROLOGY , cilt.16, sa.2, ss.72-77, 2010 (ESCI, Scopus, TRDizin)

107. An unusual central nervous system involvement in rheumatoid arthritis: combination of pachymeningitis and cerebral vasculitis

Kurne A., KARABUDAK R., KARADAĞ Ö., Yalcin-Cakmakli G., Karli-Oguz K., Yavuz K., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.29, sa.11, ss.1349-1353, 2009 (SCI-Expanded, Scopus)

108. The validity and test-retest reliability of the Leeds Multiple Sclerosis Quality of Life scale in Turkish patients

Akbiyik D. I., Sumbuloglu V., Guney Z., ARMUTLU K., Korkmaz N., KESER İ., et al.

INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH , cilt.32, sa.2, ss.162-166, 2009 (SSCI, Scopus)

109. Interferon-beta Theraphy in Multiple Sclerosis Patients: is Response Age Dependent?

Kurne A., TERZİ M., Aydin O. F., ONAR M. K., KARABUDAK R.

JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH , cilt.26, sa.2, ss.131-138, 2009 (SCI-Expanded, Scopus, TRDizin)

110. Use of Mitoxantrone in Early Secondary Progressive Multiple Sclerosis: An Observational Study of 48 Patients with Clinical and MRI Outcomes

Kilic A. K., Kurne A., BAŞTAN B., Cikrikci I., Bas D. F., Bulus M., et al.

TURKISH JOURNAL OF NEUROLOGY , cilt.15, sa.2, ss.64-70, 2009 (ESCI, TRDizin)

111. A clinically isolated syndrome: A challenging entity

Kurne A., Isikay I. C., Karlioguz K., KALYONCU U., AYDIN Ö. F., Calguneri M., et al.

JOURNAL OF NEUROLOGY , cilt.255, sa.11, ss.1625-1635, 2008 (SCI-Expanded, Scopus)

112. Soluble trail and BAFF levels in multiple sclerosis during interferon-beta therapy

Kurne A., Aydin O. F., Guec D., Sayat G., Canpinar H., Yoeruebulut M., et al.

JOURNAL OF NEUROIMMUNOLOGY , cilt.203, sa.2, ss.137-138, 2008 (SCI-Expanded, Scopus)

113. Recurrent alien hand syndrome in a multiple sclerosis case

Kurne A., Cakmakli G. Y., KARABUDAK R.

NEUROLOGIST , cilt.14, sa.5, ss.316-317, 2008 (SCI-Expanded, Scopus)

114. Evaluating the Existence of Other Autoimmune Diseases Among Multiple Sclerosis Patients and Their First Degree Relatives

Kurne A., Terzi M., Erturk O., Onar M., Dogan B. G., KARABUDAK R.

TURKISH JOURNAL OF NEUROLOGY , cilt.14, sa.2, ss.104-109, 2008 (ESCI, TRDizin)

115. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

Goodin D. S., Biermann L. D., Bohlega S., Boiko A., Chofflon M., Gebeily S., et al.

CURRENT MEDICAL RESEARCH AND OPINION , cilt.23, sa.11, ss.2823-2832, 2007 (SCI-Expanded, Scopus)

116. White matter alteration in a patient with Graves' disease

Kurne A., Aydin O. F., Karabudak R.

JOURNAL OF CHILD NEUROLOGY , cilt.22, sa.9, ss.1128-1131, 2007 (SCI-Expanded, Scopus)

117. Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients

Armutlu K., Keser I., Koikmaz N., Akbiyik D. I., Sumbuloglu V., Guney Z., et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES , cilt.255, ss.64-68, 2007 (SCI-Expanded, Scopus)

118. The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients

Armutlu K., Korkmaz N. C., Keser I., Sumbuloglu V., Akbiyik D. I., Guney Z., et al.

INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH , cilt.30, sa.1, ss.81-85, 2007 (SSCI, Scopus)

119. Aphasic status epilepticus with periodic lateralized epileptiform discharges in a bilingual patient as a presenting sign of "AIDS-toxoplasmosis complex"

OEZKAYA G., Kurne A., Uenal S., Oguz K. K., Karabudak R., Saygi S.

EPILEPSY & BEHAVIOR , cilt.9, sa.1, ss.193-196, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

120. Steps in the Pathogenesis of Multiple Sclerosis - I: From Neuroinflammation to Neurodegeneration

Kurne A., KARABUDAK R., AYDIN Ö. F.

TURKISH JOURNAL OF NEUROLOGY , cilt.12, sa.1, ss.5-13, 2006 (ESCI, TRDizin)

121. Steps in Multiple Sclerosis Pathogenesis - II: The Role of Biological Markers, Sodium Channels and Glutamate in Neurodegeneration

AYDIN Ö. F., Kurne A., KARABUDAK R.

TURKISH JOURNAL OF NEUROLOGY , cilt.12, sa.2, ss.98-105, 2006 (ESCI, TRDizin)

122. The colorful clinical spectrum of cerebral toxoplasmosis in five HIV positive cases: What comes out of Pandora's box? HIV pozitif beş olguda serebral toksoplazmozisin renkli klinigi: Pandora'nιn kutusundan çιkanlar

Kurne A., Özkaya G., Karlioǧuz K., Shorbagi A., Ustaçelebi Ş., KARABUDAK R., et al.

Mikrobiyoloji Bulteni , cilt.40, sa.1-2, ss.85-92, 2006 (Scopus)

123. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients - One year follow-up results

KARABUDAK R., KURNE A., GUC D., Sengelen M., CANPINAR H., KANSU E.

JOURNAL OF NEUROLOGY , cilt.251, sa.3, ss.279-283, 2004 (SCI-Expanded, Scopus)

124. Multiphasic disseminated encephalomyelitis: A 4-year follow-up

Ünal I., DOǦULU F. Ç., SAYGI S., FIRAT M., RUACAN Ş., KARABUDAK R.

European Neurology , cilt.43, sa.1, ss.55-58, 2000 (SCI-Expanded, Scopus)

125. Familial Mediterranean fever and multiple sclerosis

TOPÇUOĞLU M. A., KARABUDAK R.

JOURNAL OF NEUROLOGY , cilt.244, sa.8, ss.510-514, 1997 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 35

1. Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; data from the Phase IIIb ENSEMBLE study

Patti F., Bermel R., Brochet B., Berger T., Carroll W., Freedman M. S., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.594-596, (Özet Bildiri)

2. The Effect of Pregnancy on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Associated Disease Activity and Progression: A Multi-center Retrospective Study from Turkey

Uzunkopru C., Şen S., Altintas A., ÇAKAN ERCAN M., BÜNÜL S. D., Demir G. A., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.664, (Özet Bildiri)

3. Clinical Features, Treatment and Outcomes of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS) - An Experience from a Tertiary Center

Ozbek E. D., ACAR ÖZEN N. P., GÖÇMEN R., Tan E., KARABUDAK R., TUNCER M. A.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.654, (Özet Bildiri)

4. Evaluation of Nutritional Status in Patients with Multiple Sclerosis

ATABİLEN B., AKDEVELİOĞLU Y., ACAR ÖZEN N. P., KARABUDAK R., TUNCER M. A.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.1043-1044, (Özet Bildiri)

5. The Impact of COVID-19 Infection on Multiple Sclerosis Disease Course: A Propensity-Matched Cohort Study

Levitz D., Foong Y. C., Sanfilippo P., Spelman T., Rath L., Roldan A., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.1046-1048, (Özet Bildiri)

6. Comparison of Clinical Features of Aquaporin-4 Positive Neuromyelitis Optica Spectrum Disorder (NMOSD), Myelin Oligodendrocyte Glycoprotein (MOG) Associated Disorder, and Seronegative NMOSD - A Single Center Experience

Ozbek E. D., ÇAKAN ERCAN M., ACAR ÖZEN N. P., ÇOLPAK IŞIKAY A. İ., KAŞIKCI ÇAVDAR M., KARABUDAK R., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.660-661, (Özet Bildiri)

7. Disease activity during pre-conception, pregnancy and postpartum in women with MS receiving ocrelizumab or other disease-modifying therapies in a real-world cohort

Yeh W., Van der Walt A., Skibina O., Kermode A., Pedrini M., Kalincik T., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.129-132, (Özet Bildiri)

8. Real World Ocrelizumab Experience of a Tertiary Center in Turkey

ARSLAN D., Acar-Ozen N. P., KARABUDAK R., Tuncer A.

Virtual Annual Meeting of the American-Academy-of-Neurology, ELECTR NETWORK, 17 - 22 Nisan 2021, cilt.96, (Özet Bildiri)

9. DİNAMİK KONTRAST MR PERMEABİLİTE GÖRÜNTÜLEMENİN NÖROMYELİTİS OPTİKA SPEKTRUM HASTALARINDA AQUAPORİN KANAL DİSFONKSİYONUNUN GÖSTERİLMESİNDE YERİ OLABİLİR Mİ ?

OKAR S. V., GÖÇMEN R., PARLAK Ş., ERDENER Ş. E., KARLI OĞUZ H. K., KARABUDAK R., et al.

55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)

10. HEMORAJİK LONGİTUDİNAL EKSTENSİF TRANSVERS MİYELİT: 4 OLGU

YILMAZ E., GÖÇMEN R., KARABUDAK R., KARLI OĞUZ H. K., TUNCER M. A.

55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)

11. Dinamik Kontrast MR Permeabilite Görüntülemenin Nöromyelitis Optika Spektrum Hastalarında Aquaporin Kanal Disfonksiyonunun Gösterilmesinde Yeri Olabili rmi

Okar S., GÖÇMEN R., PARLAK Ş., ERDENER Ş. E., KARLI OĞUZ H. K., KARABUDAK R., et al.

55. Ulusal Nöroloji Kongresi, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)

12. Transcriptomic and immunophenotypic analyses on natural killer cells in RRMS patients under fingolimod therapy

Acar-Ozen N. P., TUNCER A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.664-665, (Özet Bildiri)

13. BK virus can be neurotropic: a rare cause of PML

AYVACIOĞLU C., KARABUDAK R., TUNCER A., ÖGE D. D., ELİBOL B., Tan E., et al.

14. Radyolojik İzole Sendromlu Bireylerde Temporal Peripapiller Retinal Sinir Lifi Tabakası Kalınlığının Azalması ve Beyin Hacim Kaybı ile İlişkisi

VURAL A., Okar S., TUNCER M. A., Sayat G., Acar N. P., KARABULUT E., et al.

54. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 30 Kasım - 06 Aralık 2018, (Özet Bildiri)

15. ANN Classification of MS Subgroups with Diffusion Limited Aggregation

Karaca Y., Cattani C., KARABUDAK R.

18th International Conference on Computational Science and Its Applications (ICCSA), Melbourne, Avustralya, 2 - 05 Temmuz 2018, cilt.10961, ss.121-136, (Tam Metin Bildiri)

16. Can MR Permeabiltiy and Contast Enhanced (CE)-FLAIR demonstrate AQP4 Channel Dysfuncton NMOSD Patents?: Work in Progress

OKAR S. V., GÖÇMEN R., TUNCER M. A., KARLI OĞUZ H. K., ERDENER Ş. E., KARABUDAK R.

MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, Fransa, 25 - 28 Ekim 2017, (Özet Bildiri)

17. Can MR permeability and contast enhanced (CE)-FLAIR demonstrate AQP4 channel dysfunction in NMOSD patients? Work in progress

OKAR S. V., GÖÇMEN R., KARLI-OGUZ K., TUNCER M., Erdener S. E., KARABUDAK R.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.819-820, (Özet Bildiri)

18. Spectrum of autoantibodies against myelin oligodendrocyte glycoprotein

VURAL A., TUNCER M. A., M SPADARO M., KONUŞKAN B., GÖÇMEN R., ANLAR F. B., et al.

3rd Congress of the European Academy of Neurology, Amsterdam, Hollanda, 24 - 27 Haziran 2017, cilt.24, ss.19-122, (Özet Bildiri)

19. The Maculo-Papillary Bundle and Inner Ganglion Cell Layer Are Affected More Prominently in Radiologically Isolated Syndrome

KARABUDAK R., Vural A., Acar N. P., TUNCER M. A., Sayat G., KADAYIFÇILAR S.

9th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Bangkok, Tayland, 27 - 29 Ekim 2016, cilt.23, ss.326, (Özet Bildiri)

20. The effect of fingolimod treatment on natural killer cells

Acar N. P., KARABUDAK R., Ozkazanc D., Sayat-Gurel G., ESENDAĞLI G., TUNCER A.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.176-177, (Özet Bildiri)

21. Leptomeningeal contrast enhancement in patients with neuromyelitis optica disorder

OKAR S. V., TUNCER M. A., GÖÇMEN R., ÇOLPAK IŞIKAY A. İ., yılmaz e., KARABUDAK R.

32ND CoNgressof the europeaN Committeefor treatmeNt aND researChiN multiple sClerosis, Londrina, Brezilya, 14 Haziran - 17 Eylül 2016, (Özet Bildiri)

22. Factors Affecting Bone Mineral Density Among Male Primary Progressive Multiple Sclerosis Patients

ÇALIŞKAN A., KUTSAL F. Y., ACAR P., KARABUDAK R., AKBIYIK F., KARAHAN S.

WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Malaga, İspanya, 14 - 17 Nisan 2016, cilt.27, (Özet Bildiri)

23. Disease activity in Primary Progressive Multiple Sclerosis

Vural A., Kurne A. T., Sayat G., Derle E., KARABUDAK R.

ACTRIMS Forum, Louisiana, Amerika Birleşik Devletleri, 18 - 20 Şubat 2016, cilt.22, ss.30, (Özet Bildiri)

24. Rituximab experience in neuromyelitis optica: data from a single center in Turkey

ERDENER Ş. E., DIKER S., KARABUDAK R., KURNE A. T.

Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.21, ss.454, (Özet Bildiri)

25. Formyl-methionyl-leucyl-phenylalanine (fMLP) peptide as an adjuvant in experimental autoimmune encephalomyelitis (EAE): modulation of neutrophil granulocytes

KILIÇ A., Tuncer-Kurne A., ESENDAĞLI G., Sayat G., TALİM B., KARABUDAK R.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.136, (Özet Bildiri)

26. Inflammatory pan-demyelination syndrome IPANDS of the whole nervous system

Vural A., GÜLER E., GÖÇMEN R., TUNCER M. A., KARLI OĞUZ H. K., TEMUÇİN Ç. M., et al.

2013 Meeting of the Peripheral Nerve Society, Fransa, 29 Haziran - 03 Temmuz 2013, cilt.18, ss.1-131, (Özet Bildiri)

27. Evaluation of Th17-related parameters in multiple sclerosis patients under immunomodulatory IFN-beta 1 therapy

Sayat G., Kurne A., ESENDAĞLI G., Guc D., KARABUDAK R.

11th International Congress of Neuroimmunology (ISNI), Massachusetts, Amerika Birleşik Devletleri, 4 - 08 Kasım 2012, cilt.253, ss.77-78, (Özet Bildiri)

28. Walking and Expanded Disability Status Scale: are self-estimated walking distances accurate?

Armuthu K., Balci K., FİL BALKAN A., KARABUDAK R.

13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Kanada, 17 - 20 Eylül 2008, cilt.14, (Özet Bildiri)

Metrikler

Yayın

160

Yayın (WoS)

150

Yayın (Scopus)

121

Atıf (WoS)

610

H-İndeks (WoS)

Atıf (Scopus)

403

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler